Subsidised access to TNF-α inhibitors: Is the rationale for exclusion of rheumatoid-factor-negative patients defensible? [8]

Medical Journal of Australia

Volumn 182, Issue 1, 2005, Pages 47-48

  Mann, Erica L ^a  

^a Wyeth Australia and New Zealand   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ETANERCEPT; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; HEALTH CARE ACCESS; HUMAN; LETTER; MONOTHERAPY; PAIN ASSESSMENT; PHYSICAL DISABILITY; RHEUMATOID ARTHRITIS;

EID: 11844262650     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06566.x     Document Type: Letter

References (2)

1. Lu CY, Williams KM, March L, et al. Subsidised access to TNFα inhibitors: is the rationale for exclusion of rheumatoid factor negative patients defensible? [letter]. Med J Aust 2004; 181: 457.
2. Klareskog L, van Der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-681.